RxDoctor Payments Data

Subodh Bhuchar, MD

Family Medicine · Sugar Land, TXNPI 1629082417

Payments from drug & device makers

$1,217,716in general payments, 2019–2025

Across 704 payments — averaging $1729.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astrazeneca UK Limited$291K
  • Ardelyx, Inc.$261K
  • AstraZeneca$144K
  • GSK$139K
  • Amgen$111K
  • AbbVie$100K
  • plus $172K from 40 others

What the payments were for

  • Food & beverage$8,296100%
  • Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,217,716 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$140,525
Medicare patients
216
Services billed
2,165

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide80$144,122
JardianceEmpagliflozin69$99,430
JanuviaSitagliptin Phosphate36$52,204
MounjaroTirzepatide34$50,771
FarxigaDapagliflozin Propanediol28$34,487
TrulicityDulaglutide22$26,908
EliquisApixaban20$26,468
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$24,196
VascepaIcosapent Ethyl29$21,263
ProliaDenosumab12$20,398
JanumetSitagliptin Phos/Metformin Hcl11$14,484
ArexvyRsvpref3 Antigen/As01e/Pf37$11,560
Tresiba Flextouch U-200Insulin Degludec12$6,824
Lantus SolostarInsulin Glargine,hum.Rec.Anlog51$5,135
Colesevelam Hcl13$4,780

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,236$144,12280 claims
Boehringer IngelheimJardiance$694$99,43069 claims
Lilly USA, LLCMounjaro, Trulicity$715$77,67956 claims
MerckJanuvia, Janumet$423$66,68747 claims
GSKTrelegy Ellipta, Arexvy$138,579$35,75663 claims
AstraZenecaFarxiga$144,144$34,48728 claims
PfizerEliquis$196$26,46820 claims
AmgenProlia$110,540$20,39812 claims
AbbVieSynthroid$99,849$1,26214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Sugar Land

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →